30.01.2018 • NewsBayerElaine BurridgeEU

EU Extends Bayer-Monsanto Deadline

Bayer’s proposed acquisition of Monsanto faces another delay after European...
Bayer’s proposed acquisition of Monsanto faces another delay after European regulators extended their investigation by five days to Mar. 12. (c) Bayer

Bayer’s proposed acquisition of Monsanto faces another delay after European regulators extended their investigation by five days to Mar. 12.

The European Commission has not given a reason for the extension, which effectively gives the German group a new deadline of midnight on Feb. 5 to propose further concessions. The deadline has already been extended once after the Commission opened an in-depth review of the merger last August.

Bayer has already committed to sell certain crop science businesses to German rival BASF for €5.9 billion but is said to be bracing itself for antitrust authorities to require further asset sales.

India also raised its concerns on the merger earlier this month. The Competition Commission of India (CCI) said that Bayer’s proposed buyout of Monsanto would adversely hit competitors’ operations. Consequently, the antitrust authority launched a public consultation on Jan. 5.

However, according to reports in the Indian media, Bayer said it was still confident of getting approval from the CCI, hopefully by April/May.

The deal is now valued at $63.5 billion including debt, which is $2.5 billion less than the initial price tag of $66 billion after Monsanto lowered its financial liabilities last October.

If it goes ahead, the transaction would make Bayer the world’s largest supplier of seeds and agrochemicals, surpassing ChemChina, which acquired Syngenta last year, DowDuPont and BASF.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis